Factor VIII peptide-HLA class II complex (FVIII-HLA)

The Factor VIII peptide-HLA complex is an assembly where peptide fragments from the Factor VIII protein are presented by HLA class II molecules on the surface of antigen-presenting cells. This complex is critical in the immune response against therapeutic Factor VIII in hemophilia A patients—those whose immune system recognizes Factor VIII as foreign, leading to the development of neutralizing antibodies ("inhibitors") that block its therapeutic effect. Strategies to reduce immunogenicity of Factor VIII therapy have focused on modifying Factor VIII peptides to diminish their binding affinity for HLA class II molecules, thereby decreasing T-cell mediated immune responses. The formation and presentation of these complexes are tightly linked to patient HLA genotype, influencing both susceptibility and the clinical outcome of protein replacement therapies in hemophilia.

Other names

FVIII peptide-MHC complexFactor VIII peptide-MHC class II complexFactor VIII epitope-HLA complex

Modified Factor VIII proteins: engineered to reduce affinity for HLA binding pockets, thus diminishing immunogenic peptide presentation and T cell activation